Skip to Main Content

Reverse Payments After Actavis: Fifteen Cases to Follow

Published by Bloomberg BNA
Article | July 11, 2014

A year after the Supreme Court's ruling in FTC v. Actavis, Inc., this article discusses fifteen ongoing cases that implicate "pay for delay" settlements in pharmaceutical patent litigation. It highlights key issues in dispute in each of these cases as the courts apply the "rule of reason" in novel and complex contexts.

Katten Websites   Careers  |  Alumni  |  Mobile Site
Contact Us   Offices  |  Media Center  |  People  |  Email
Legal Notices   Disclaimer  |  Privacy Notice  |  Cookie Notice  |  United Kingdom Notices  | Accessibility 
Attorney Advertisting. © 2019 Katten Muchin Rosenman LLP